Login

Switch On Your HIV Smarts.

New antibody therapy “profoundly” successful at reducing inflammation from HIV

New antibody therapy “profoundly” successful at reducing inflammation from HIV

, by Emily Newman

With just one dose, canakinumab reduced markers of inflammation and improved arterial function in people living with HIV. Read More

Antibody therapies effective at preventing HIV from invading CD4 cells

Antibody therapies effective at preventing HIV from invading CD4 cells

, by Liz Highleyman

Research on two new long-acting antibody therapies demonstrates success at protecting CD4 cells and suppressing viral loads in people living with HIV. Read More

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

, by Liz Highleyman

Two new HIV drugs, an NNRTI and an integrase inhibitor, did well in clinical trials and are currently being tested as part of fixed-dose co-formulated pills. Read More

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

Simpler HIV treatment, with only 2 drugs, keeps viral loads suppressed

, by Liz Highleyman

People taking only two drugs, dolutegravir and rilpivirine, maintained viral suppression in participants of the SWORD-1 an SWORD-2 studies. Read More

Sci-fi ways to treat HIV: Implants, monoclonal antibodies & more

Sci-fi ways to treat HIV: Implants, monoclonal antibodies & more

, by Emily Newman

Researchers are working on new treatment options that will make treating HIV easier than ever before. Read More